Rundu Co., Ltd. announced that the company recently received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for vonoracen fumarate issued by the State Drug Administration to approve registration. The company submitted a marketing application for domestically produced chemical raw materials in May 2025 and was accepted. It received a CDE supplementary research notice in March 2026, completed the supplementary research and submitted data in July 2026, and obtained an approval notice in November 2026. Vonoracin fumarate tablets are used for reflux esophagitis and used in combination with appropriate antibiotics to eradicate Helicobacter pylori. This approval helps improve the company's product layout in the field of digestive system treatment.

Zhitongcaijing · 1d ago
Rundu Co., Ltd. announced that the company recently received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for vonoracen fumarate issued by the State Drug Administration to approve registration. The company submitted a marketing application for domestically produced chemical raw materials in May 2025 and was accepted. It received a CDE supplementary research notice in March 2026, completed the supplementary research and submitted data in July 2026, and obtained an approval notice in November 2026. Vonoracin fumarate tablets are used for reflux esophagitis and used in combination with appropriate antibiotics to eradicate Helicobacter pylori. This approval helps improve the company's product layout in the field of digestive system treatment.